To elucidate whether the induction of FH-binding molecules such as Pra1 or Hgt1 may represent a new therapeutic approach to tackle Candida infections, a mutant overexpressing Pra1 or Hgt1 has to be generated. This evidence concerns the gene SLC25A16 and candidiasis.